Cosentyx wins EU approval for first-line paediatric psoriasis
Low-dose and high-dose Cosentyx is effective in rapidly improving skin symptoms and quality of life
Read More
Tag: Consentyx
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
